Company news

COSCIENS Biopharma Inc. news in 2014

COSCIENS Biopharma Inc.'s news releases, calls and decks from 2014, newest first.

View company

Aeterna Zentaris: Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin in Prostate Cancer Published in Clinical Cancer Research

December 29, 2014

Aeterna Zentaris Receives Notification from NASDAQ Relating to Minimum Bid Price

December 19, 2014

Aeterna Zentaris and Sinopharm A-Think Sign Master Collaboration Agreement for Zoptarelin Doxorubicin in China

December 1, 2014

Aeterna Zentaris Adds Hollings Cancer Center to Multi-National Phase 3 Trial in Endometrial Cancer

November 20, 2014

FDA Issues Complete Response Letter for Aeterna Zentaris' Macrilen(TM) NDA in Adult Growth Hormone Deficiency

November 6, 2014

Correction: Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions

November 5, 2014

Aeterna Zentaris Reports Third Quarter 2014 Financial and Operating Results

November 4, 2014

Aeterna Zentaris to Announce Third Quarter 2014 Financial and Operating Results on November 4, 2014

October 28, 2014

Aeterna Zentaris Announces Formal Implementation of its Sales Force In Support of Selling ASCEND's EstroGel®

October 27, 2014

Aeterna Zentaris Appoints Phil Theodore as Chief Administrative Officer, General Counsel and Corporate Secretary

October 7, 2014

Aeterna Zentaris Reports Second Quarter 2014 Financial and Operating Results

August 7, 2014

Aeterna Zentaris to Present at Upcoming Canaccord Genuity 34th Annual Global Growth Conference in Boston

August 6, 2014

Aeterna Zentaris and ASCEND Therapeutics Sign Co-Promotion Agreement for U.S. Market

August 5, 2014

Aeterna Zentaris to Announce Second Quarter 2014 Financial and Operating Results on August 7, 2014

July 31, 2014

Aeterna Zentaris to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference in Toronto

June 11, 2014

Aeterna Zentaris Implements Global Resources Optimization Program as Part of its Transition into a Commercially Operating Specialty Biopharmaceutical Company

June 10, 2014

Aeterna Zentaris: Poster Presented at ASCO Meeting on the Design of the Current ZoptEC Phase 3 Trial in Endometrial Cancer

June 2, 2014

Aeterna Zentaris: Poster to be Presented on the Design of Current ZoptEC Phase 3 Trial in Endometrial Cancer with Zoptarelin Doxorubicin at ASCO

May 22, 2014

Aeterna Zentaris Announces Board of Directors Leadership Change and Election of Directors at Annual Meeting of Shareholders

May 12, 2014

Aeterna Zentaris Announces At the Market Issuance Program

May 9, 2014

Aeterna Zentaris Reports First Quarter 2014 Financial and Operating Results

May 8, 2014

Aeterna Zentaris Selects Charleston, S.C. as New Location for its North American Business and Global Commercial Operations

May 5, 2014

Aeterna Zentaris to Announce First Quarter 2014 Financial and Operating Results on May 8, 2014 and Hold Annual Shareholders Meeting on May 9, 2014

April 30, 2014

Aeterna Zentaris: Poster Presentation at AACR Meeting Provides Rationale for New Therapeutic Opportunities in Oncology with Erk Inhibitors

April 9, 2014

Aeterna Zentaris to Present Poster on New Therapeutic Opportunities in Oncology with Erk Inhibitors at AACR Meeting in San Diego

April 1, 2014

Aeterna Zentaris Announces Effectiveness of $50 Million Shelf Registration Statement for "At-the-Market" Common Share Issuance Programs

March 28, 2014

Aeterna Zentaris Reports Fourth Quarter and Full-Year 2013 Financial and Operating Results

March 20, 2014

Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2013 Financial and Operating Results on March 20, 2014

March 12, 2014

Aeterna Zentaris: Article on Phase 2 Results for Zoptarelin Doxorubicin in Endometrial Cancer Published in the International Journal of Gynecological Cancer

February 4, 2014

Aeterna Zentaris: Presentations on Zoptarelin Doxorubicin and Disorazol Z Conjugates at Upcoming International Symposium on GnRH

February 3, 2014

Aeterna Zentaris Announces Closing of US$13.2 Million Public Offering of Common Shares and Warrants

January 14, 2014

Aeterna Zentaris Announces Pricing of US$13.2 Million Public Offering of Common Shares and Warrants

January 9, 2014

Aeterna Zentaris NDA for Macimorelin Acetate in AGHD Accepted for Filing by the FDA

January 6, 2014

Aeterna Zentaris Appoints Dr. Richard Sachse as Chief Scientific Officer

January 3, 2014